Sphingosine-1-phosphate Signaling and the Chronic Glucocorticoid Exposure Induced Glucose Homeostasis Disorder
1-磷酸鞘氨醇信号转导和慢性糖皮质激素暴露引起的血糖稳态紊乱
基本信息
- 批准号:10345112
- 负责人:
- 金额:$ 39.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAttenuatedBindingBiological AssayCellsCholesterolChronicDiseaseEnzymesExposure toExtracellular SpaceFunctional disorderGene ExpressionGene Expression ProfilingGenesGenetic TranscriptionGlucocorticoid ReceptorGlucocorticoidsGluconeogenesisGlucoseHepaticHepatocyteHyperglycemiaImmuneInflammatoryKnockout MiceKnowledgeLiverMAPK1 geneMAPK3 geneMediatingMembraneMetabolic DiseasesMetabolismModelingMusNon-Insulin-Dependent Diabetes MellitusOrphanPathway interactionsPatientsPharmacotherapyPhysiologicalPlayProductionPyruvateRattusRegulationResponse ElementsRoleSPHK1 enzymeSignal TransductionSignaling MoleculeSphingosineSphingosine-1-Phosphate ReceptorSteroidsStressSurfaceTestingTherapeutic Interventionbaseblood glucose regulationcholesterol biosynthesischromatin immunoprecipitationcomorbidityextracellulargenome-widehepatic gluconeogenesishepatoma cellimprovedin vivoinhibitor/antagonistinsightknock-downnew therapeutic targetnoveloverexpressionreceptorrecruitresponsesphingosine 1-phosphatesphingosine kinasetranscriptome
项目摘要
SUMMARY
Chronic and/or excess glucocorticoid (GC) exposure, such as prolonged stress and long-term GC therapy,
causes metabolic disorders including hyperglycemia. Intracellular GC receptor (GR) has been shown to directly
stimulate the transcription of gluconeogenic genes, such as Pck1 and G6pc, to promote gluconeogenesis.
However, chronic GC exposure can induce additional mechanisms to further enhance hepatic gluconeogenesis.
Our preliminary studies found that chronic GC exposure elevated hepatic sphingosine-1-phosphate (S1P) levels.
S1P is exported to the extracellular surface and binds to membrane S1P receptors (S1PRs) to exert its actions.
We found that reducing S1PR2 expression in mouse liver attenuated chronic GC exposure-promoted
gluconeogenesis. Activating S1PR2 in hepatoma cells enhanced GC-induced Pck1 and G6pc expression.
Chromatin immunoprecipitation assay found that GC-induced GR recruitment to the GC response elements
(GREs) of Pck1 and G6pc was reduced by hepatic S1PR2 knockdown. Global gene expression analysis
identified that RAR-related orphan receptor C (Rorc) expression was reduced by hepatic S1PR2 knockdown.
Rorc antagonist attenuated GC-induced gluconeogenic gene expression in hepatoma cells and overexpressing
Rorc in the liver of hepatic S1PR2 knockout mice enhanced GC-induced GR recruitment to the Pck1 and G6pc
GREs as well as their expression. Intriguingly, GC suppressed Rorc expression, which was antagonized by
S1PR2 signaling. Based on these results, we hypothesize that chronic GC exposure activates S1PR2 signaling
to enhance GC-induced gluconeogenesis by inhibiting GC’s suppressive effect on the expression of Rorc, which
can act with GR to strongly augment gluconeogenic gene transcription. In Aim 1, we will test if altering
intracellular S1P levels in hepatocytes affects chronic GC treatment-induced hyperglycemia by overexpressing
or knocking down Sphk1 and Sphk2 (both convert sphingosine to S1P), Sgpl1 (hydrolyzes S1P) and Spns2
(exports S1P to extracellular space) in mouse liver. In Aim 2, we will establish Rorc’s in GC-induced hepatic
gluconeogenesis by reducing hepatic Rorc expression or treating mice with Rorc antagonist. Notably, 4a-
carboxy, 4b-methyl-zymosterol (4ACD8), a metabolite of cholesterol biosynthesis, has been shown to be a Rorc
agonist. We will investigate whether reducing the expression of Sc4mol, an enzyme generating 4ACD8,
attenuates the GC effect on hepatic gluconeogenesis. In Aim 3, we will identify signaling molecules activated by
S1PR2 that participate in GC regulation of gluconeogenic genes and Rorc expression. We will also analyze the
role of Rorc in GR regulated global hepatic gene transcription. Finally, how GC and S1PR2 signaling regulate
Rorc expression will be investigated. Overall, the proposed studies will establish a novel S1PR2-Rorc axis
induced specifically upon chronic GC exposure to enhance GC activated gluconeogenesis. Not only will this
knowledge advance our understand on pathophysiology of chronic GC exposure, but it also will provide novel
targets for therapeutic intervention against steroid induced hyperglycemia.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jen-Chywan Wang其他文献
Jen-Chywan Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jen-Chywan Wang', 18)}}的其他基金
Sphingosine-1-phosphate Signaling and the Chronic Glucocorticoid Exposure Induced Glucose Homeostasis Disorder
1-磷酸鞘氨醇信号转导和慢性糖皮质激素暴露引起的血糖稳态紊乱
- 批准号:
10666581 - 财政年份:2021
- 资助金额:
$ 39.26万 - 项目类别:
Glucocorticoid Receptor Coregulators and Insulin Sensitivity
糖皮质激素受体共调节剂和胰岛素敏感性
- 批准号:
10317109 - 财政年份:2020
- 资助金额:
$ 39.26万 - 项目类别:
Glucocorticoid Receptor Coregulators and Insulin Sensitivity
糖皮质激素受体共调节剂和胰岛素敏感性
- 批准号:
10521257 - 财政年份:2020
- 资助金额:
$ 39.26万 - 项目类别:
Regulation of Insulin sensitivity by Glucocorticoid-Angiopoietin-like 4-Ceramide Axis
糖皮质激素-血管生成素样 4-神经酰胺轴调节胰岛素敏感性
- 批准号:
10064621 - 财政年份:2017
- 资助金额:
$ 39.26万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 39.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 39.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 39.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




